One major problem associated with application of gene therapy to treatment of tumors is poor transgene expression. Although suicide gene therapy with the herpes simplex virus-thymidine kinase gene (HSV-tk) followed by administration of ganciclovir (GCV) was effective in the treatment of melanoma, it was still difficult to induce complete remission to cancer. A novel histone deacetylase inhibitor drug FR901229 was found to enhance transgene expression in tumor cells both in vitro and in vivo. Combination therapy with HSV-tklGCV and FR901228 by direct injection into tumor enhanced antimelanoma effects. The number of apoptotic cells in melanoma tumors was increased significantly (Po.05) after combined suicide gene therapy and FR901228. Six times injection of HSV-tk/GCV and FR901228 prolonged mice survival compared to that of HSV-tk/GCV injection alone (P ¼ .021). In total, 56% (10 of 18) of the mice survived 120 days after combined suicide gene therapy and FR901228 treatment, and no new tumors appeared in the surviving mice. However, only 19% (3 of 16) of the mice survived when treated with suicide gene therapy alone. This novel strategy may be applicable as a therapeutic regimen for the treatment of aggressive types of cancers.
S
ince the early 1990s, gene therapy has been proposed as a strategy for the treatment of intractable human diseases. More than 500 clinical gene therapy protocols have been undertaken, and approximately 70% of these were for cancer (http://www.wiley.co.uk/genetherapy/). However, remarkable success in human gene therapy has not yet been obtained. These treatments may be hindered by gene-related problems such as low gene transfection efficiency and poor transgene expression. Among the many technical challenges associated with in vivo cancer gene therapy are the need to enhance gene expression and the need to develop more effective vectors. Numerous viral and nonviral (synthetic) methods of gene transfer have been developed. 1, 2 Each delivery system has limitations as well as advantages, and further improvement of gene transfer vector systems will be obviously inevitable in the future. Regardless of vector development, it has been elucidated that silencing of transgene expression occurs in host cells, even though transgenes are retained in the host cell nucleus. 3 Similar silencing has also been reported in certain viral infections. For example, retroviral gene expression was inhibited after retrovirus infection of mouse embryos. 4, 5 Although low or silenced transgene expression after transfection has been a major problem in human gene therapy, 6 the mechanism(s) by which transgene expression is regulated has not yet been reported. Recent studies on chromatin remodeling revealed that histone acetylase and deacetylase also regulate the level of transcription by modifying chromatin. 7, 8 Agents, including trichostatin A (TSA), trapoxin (TPX), and n-butyrate, that inhibit histone deacetylation have been identified. 9, 10 With the use of these agents, reactivation of virally transduced genes 11 and amplified expression of transgenes encoded by the recombinant adenovirus vector 12 have been reported. These data suggest that transgene expression can be regulated by chromatin modifications such as histone acetylation/ deacetylation. Recently, amplification of transgene expression in cultured cells was also achieved by a novel histone deacetylase inhibitor, FR901228, which is derived from Chromobacterium violaceum. 13, 14 This drug was first developed as an anticancer reagent because it induced growth arrest, differentiation, and/or apoptotic cell death. 15 Therefore, we attempted to evaluate the anticancer effect of the combination of cancer gene therapy and FR901228.
Among various strategies of cancer gene therapy, we chose suicide gene therapy using herpes simplex virusthymidine kinase gene (HSV-tk)/ganciclovir (GCV) 16 because suicide gene therapy has multiple effects on killing cancer cells such as bystander effect 17 and induction of tumor immunity. 18 Here, we showed that this combination therapy could induce complete responses without recurrence in melanoma-bearing mice.
Methods

Construction of plasmid DNA
Luciferase (pcLuci: 7.4 kb) was constructed by cloning the luciferase gene from pGEM-luci (Promega, Madison, WI, USA) into pcDNA3 (Invitrogen, San Diego, CA, USA) at the HindIII and BamHI sites. The EcoRI-XhoI fragment of the HSV-tk gene was cloned into pcDNA3 to generate pc-tk (7.14 kb). The pc-LacZ (9.2 kb) construct was generated by insertion of the HindIII-BamHI fragment of pSV-b-galactosidase (Promega) into pcDNA3.
Preparation of HVJ-liposomes
Cholesterol (Chol), egg yolk phosphatidylcholine (ePC), egg yolk sphingomyelin (eSph), dioleoylphosphatidylethanolamine (DOPE), and 3-beta {N-(N 0 ,N 0 -dimethylaminoethane)-carbamoyl} cholesterol (DC-Chol) were purchased from Sigma Chemical Co. (St Louis, MO, USA). To prepare HVJ-liposomes, ePC, eSph, DOPE, Chol, and DC-Chol were mixed at a molar ratio of 16.7 : 16.7 : 16.7 : 40 : 10 as described previously. 19, 20 For transfection of the luciferase gene or LacZ gene, 200 mg of plasmid (pcLuci and pc-LacZ) was incorporated into liposomes prepared from 10 mg of lipids, and the liposomes were fused with inactivated HVJ (hemagglutinating virus of Japan; Sendai virus). The HVJ-liposome complexes were then separated from free HVJ by sucrose density gradient centrifugation. For in vivo transfection of HSV-tk gene, 200 mg pc-tk and 151.2 mg pcDNA3 plasmid (equal number of copies as pc-tk) were used. The final HVJ-liposome volume was approximately 200 ml.
Cell lines and drugs
Mouse melanoma B16F1 cells (American Type Culture Collection, Rockville, MD, USA) were seeded at 1 Â 10 5 cells per well in six-well plates. Cells were maintained in Dulbeco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin (50 unit/ml), and streptomycin (50 mg) and incubated at 371C in a 5% CO 2 -95% air atmosphere. Tissue culture medium and supplements were purchased from Nakarai Tesque (Kyoto, Japan). The following drugs were used in the study: GCV (Tanabe Seiyaku Co. Ltd, Osaka, Japan) and FR901228 (Exploratory Research Laboratories of Fujisawa Pharmaceutical Co. Ltd, Tsukuba, Japan). FR901228 was dissolved and diluted in phosphate-buffered saline (PBS, pH 7.4) to 250 mg/ml as described previously. 21 For in vivo experiments, FR901228 solution was mixed with HVJ-liposomes, and injected directly into tumors.
Animal experiments
All animal experimental protocols were approved in a humane fashion in accordance with the guidelines of the Animal Committee of Osaka University. Male C57BL/6 mice, 8 weeks of age, were obtained from the Japan SLC, Inc. (Hamamatsu, Japan). Mice were housed five per cage and allowed access to food and water ad libitum. In all experiments, mice were anesthetized by intraperitoneal injection of diluted pentobarbital (1 mg).
For tumor cell implantation, B16F1 cells were enzymatically detached from culture flasks and counted. Five million viable cells were resuspended in 100 ml of PBS and injected subcutaneously (s.c.) into the right flank of the mice.
X-gal staining of mouse melanoma cells in vitro B16F1 cells were seeded at 1 Â 10 5 cells per well in six-well plates on day 0. After replacing the culture medium with 2 ml of fresh medium, 20 ml of HVJ-liposomes containing 1.2 mg of pc-LacZ was added to each well with or without 100 nM FR901228 solution. One hour later, cell culture medium was changed to fresh medium. At 24 h after transfection, cells were stained with 2% X-gal staining solution (2 mM MgCl 2 , 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , and 1 mg/ml X-gal in PBS) at 371C 20 overnight as described previously. 20 
In vivo luciferase assay
For luciferase assay, eight mice were used in each group. When tumors reached approximately 7-8 mm in diameter on day 7 after inoculation, 100 ml of HVJ-liposomes containing 20 mg of pcLuci mixed with various concentrations of FR901228 were injected directly into the tumors. Mice were killed and tumors were resected 24 h after injection of these HVJ-liposomes. Tumors were minced with scissors and homogenized completely in 5 Â volume of cell culture Lysis 5 Â Reagent (Promega). All steps were carried out on ice. After centrifugation at 12 000 rpm for 5 min, the supernatant was tested for luciferase activity. The luciferase activity of 20 ml of lysate was measured with a luminometer (Lumat LB 9501 luminophotometer, Belthold, Wildbad, Germany) as described previously. 20 Suicide gene therapy for tumor-bearing mice At 7 days after tumor inoculation, 100 ml of HVJliposome suspension containing pc-tk (20 mg) or pcDNA3 control (15.1 mg, same number of copies as pc-tk) was injected into mouse melanoma tumors. In the combined treatment group, 1 mg of FR901228 was mixed with HVJliposomes and injected into the tumors directly. GCV (50 mg/kg/day) was administered i.p. once daily for days [8] [9] [10] [11] [12] . After injection of HVJ-liposomes, tumor size was measured every 3 days, and the survival of the mice was monitored. Tumor volume was determined using the simplified formula of a rotational ellipse (l Â w 2 Â 0.5).
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For consecutive treatment, HVJ-liposomes or FR901228 or both were injected repeatedly at 2-day intervals, and each mouse received a total of six injections. GCV was given intraperitoneally (i.p.) for 20 days (days [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . 
TUNEL assay
On day 4 after suicide gene therapy, tumors were removed and flash frozen in liquid nitrogen. Each tumor was cut into four pieces, and frozen sections from each piece were prepared as described previously. 20 Apoptotic cells were detected with the ApopTag Plus Fluorescein In Situ Apoptosis Detection Kit (Intergen, Purchase, New York, USA) and Hoechst 33258 (Nakarai Tesque) was used for counterstaining. The efficiency of the treatment was evaluated by counting cell numbers in four sections for each group (HSV-tk/GCV with FR901228, HSV-tk/GCV pcDNA3/GCV with FR901228).
Statistical methods
Bonferroni/Dunn test was used to determine the significance of differences, and Po.05 was considered significant. The survival data were analyzed via log rank test, and Po.05 was considered significant.
Results
LacZ gene expression in vitro
We used LacZ gene as a reporter to study the effect of FR901228, which enhances transgene expression. LacZ expression was enhanced (Po.01) significantly when LacZ gene was transferred to B16F1 cells in the presence of 100 nM FR901228. At 24 h after gene transfer with FR901228, 22% (167/770) of the cells expressed the LacZ (Fig 1a) . In contrast, LacZ expression by cells not treated with FR901228 was observed in only 2% (20/855) of cells (Fig 1b) .
Luciferase assay in vivo
A luciferase assay was used to study the effect of FR901228 in vivo. HVJ-liposomes containing a vector encoding luciferase gene were injected into the mouse melanoma tumors with various concentrations of FR901228. Firstly, we tested which route of FR901228 injection enhanced luciferase expression. We tested i.p. route, intravenous (i.v.) route and direct injection route. However, neither i.p. nor i.v. route increased transgene expression remarkably at less than 10 mg/ml (1 mg/body) of FR901228 dose (data not shown). On the other hand, the direct injection of FR901228 into the tumor enhanced gene expression significantly. For that reason we selected the direct injection route.
Luciferase activity was examined 24 h after transfer. Expression of luciferase was enhanced remarkably when transfection was combined with an FR901228 injection (Fig 2a) . Luciferase activity increased in proportion to the dose of FR901228. Compared with control activity, luciferase activities of tumors treated with FR901228 were increased 8.7-fold at a dose of 10 mg/ml (1 mg/body) (Po.01) and 16.8-fold at a dose of 100 mg/ml (10 mg/body) (Po.01) on day 1 after transfection of the luciferase gene Enhanced gene therapy of melanoma S Yamamoto et al with FR901228. At concentrations of FR901228 less than 100 ng/ml, no significant gene expression was observed. On days 3 and 5, luciferase activity was not maintained (Fig 2b) .
Apoptosis of melanoma cells
We then examined whether FR901228 could enhance the effectiveness of suicide gene therapy for cancer. HSVtk gene was transfected via HVJ-liposomes into subcutaneous melanoma tumors on day 0. Tumors were injected with 10 mg/ml FR901228. GCV (50 mg/kg/day) was then administered i.p. daily for 3 days. On day 4, apoptosis was detected by both TUNEL assay and chromatin condensation with Hoechst 33258 (Fig 3) . In tumors treated with HSV-tk/GCV and FR901228 (Fig 3a,  d ), 9% (53/565) of cells were apoptotic. However, 5% (29/ 639) of cells in tumors treated with HSV-tk/GCV alone (Fig 3b, e) and only 1% (9/645) of cells treated with pcDNA/GCV and FR901228 (Fig 3c, f) showed apoptotic characteristics. The number of apoptotic cells was significantly higher in tumors treated with HSV-tk/GCV and FR901228 than in those treated with pcDNA/GCV and FR901228 (Po.01) or those treated with HSV-tk/ GCV alone (Po.01).
Combined treatment of suicide gene therapy and FR901228
To detect differences in efficacy of treatment with HSVtk/GCV alone or in combination with FR901228, we developed tumor growth curves (Fig 4) . HSV-tk or pcDNA3 with 1 mg FR901228, diluted in 100 ml of PBS, were injected into the tumor directly and GCV was administrated i.p. for the following 5 days.
Animals treated with HSV-tk/GCV alone had a significant reduction in tumor size compared with Statistical analysis showed that mean tumor volume after combined treatment with HSV-tk/GCV and FR901228 was significantly smaller than that with HSV-tk/GCV (P ¼ .023), pcDNA/GCV (Po.001), and pcDNA/GCV+ FR901228 (Po.001). Tumors in animals treated with pcDNA/GCV+FR901228 were somewhat smaller than those in control mice treated with pcDNA/GCV alone. However, this difference was not statistically significant.
To assess treatment efficacy, we monitored the survival of tumor-bearing mice after treatment. As shown in Figure 5a , untreated animals (pcDNA3/GCV) had a median survival of 34 days. Animals treated with HSVtk/GCV had significantly (Po.01) improved survival, with a median survival period of 47 days. A single injection of HSV-tk/GCV combined with FR901228 (1 mg/body) prolonged the survival period (median survival of 53 days) compared with that of mice treated with HSV-tk/GCV. However, the difference was not statistically significant (P ¼ .22). Additionally, pcDNA3/ GCV+FR901228 treatment did not improve the survival period any further (median survival of 35 days) compared with pcDNA3/GCV treatment.
Consequently, to evaluate the therapeutic effect of the combination treatment of HSV-tk/GCV and FR901228, we conducted consecutive gene therapy (Fig 5b) . With repeated injections (2, 4, and 6 times) of HSV-tk/GCV, the survival rate of tumor-bearing mice was increased (data not shown). In mice injected six times with HSV-tk/ GCV, 19% (3 of 16) showed complete remission. Consecutive treatment with HSV-tk/GCV+FR901228 Enhanced gene therapy of melanoma S Yamamoto et al was more effective than consecutive HSV-tk/GCV injection alone (P ¼ .021). When tumor-bearing mice were injected six times with HSV-tk/GCV+FR901228, 10 of 18 mice (56%) survived more than 120 days and experienced complete remission.
Discussion
We have described the in vivo amplification of transgenes by FR901228, resulting in a significant enhancement of the suicide gene therapy in melanoma-bearing mice. 
Enhanced gene therapy of melanoma S Yamamoto et al
The observation that HDAC inhibitors such as FR901228 enhance transgene expression suggests that acetylation and deacetylation of cellular proteins are involved in transgene expression. 11, 12, 14 Acetylation and deacetylation of these proteins play important roles in the regulation of gene expression. 8, [23] [24] [25] HDAC inhibitors regulate the level of transcription by modifying chromatin and activation of transcription factors. 26, 27 Our previous report 14 showed that cellular histones were highly acetylated with FR901228. We analyzed mRNA enhanced by FR901228 using DNA microarray techniques. Only 1% of approximately 7000 genes were affected by the drug, and some genes were activated and others suppressed. However, the activation or suppression was less than 4 times as much as the basal transcription level of each gene without FR901228 (Yamamoto, unpublished data). Thus, activation of gene expression with FR901228 appears to be specific to exogenous genes, although the reason for such specific activation is presently unknown. One possible mechanism is that hyperacetylation of core histones by FR901228 may be sufficient to alter the chromatin structures of exogenous genes and activate expression, but it may not affect highly condensed chromatin structures involved in endogenous gene expression. Another mechanism involves the HDAC inhibitors activation of regulatory factors of the transgene by changing the chromatin structure of genes that encode the regulatory factors 26, 27 . In this case, transgene expression may be indirectly regulated. The third possibility is direct acetylation of the transcription factors driving transgene expression by HDAC inhibitors [28] [29] [30] [31] . Gene expression is indeed activated by TSA by acetylation of transcription factors such as p53 28 and GATA-1 30 . FR901228 may have a similar action on transcription factors.
FR901228 is able to cause both a p21-dependent G 1 and a p21-independent G 2 arrest, with the G 2 arrest appearing more cytotoxic than the G 1 arrest. [32] [33] It has demonstrated potent cytotoxic activity against human tumor cell lines and in vivo efficacy against both human tumor xenografts and murine tumors. 34, 35 On the basis of such findings, FR901228 was initially tested as an anticancer drug in the Phase I clinical trial. 36 We showed here that introduction of FR901228 into the tumor mass induced apoptosis. However, the direct injection of FR901228 into the tumor at this dose (less than 1 mg/ body) was insufficient to control melanoma progression. Although the direct effect of HSV-tk/GCV induced apoptosis of cancer cells, HSV-tk/GCV alone was also insufficient (Fig 3b, e) . Nevertheless, a combination of these therapies was efficacious, and the apoptosis ratio was increased (Fig 3a, d ). FR901228 may have enhanced HSV-tk expression in transfected cancer cells and induced apoptosis in addition to its own effect.
One limitation of FR901228 as well as other HDAC inhibitors is the cytotoxicity at high doses. In our current in vivo luciferase experiments, a high dose (10 mg/body) of FR901228 was most effective for increasing the luciferase activity, but this high concentration of FR901228 induced inflammation and damaged the surrounding mouse skin. Repeated injection of FR901228 at this concentration (10 mg/body) also resulted in skin necrosis. However, the concentration of FR901228 used with gene therapy (1 mg/ body) did not cause skin necrosis.
One other limitation of FR901228 is short half-life. The mean terminal half-life of FR901228 is 87 min, 21 and therefore the effect of the drug was only transient and high gene expression was not maintained. On days 3 and 5, luciferase activity in tumors transfected with luciferase gene combined with FR901228 was nearly the same as the activity in control tumors that received gene transfection alone (Fig 2b) . Because of the short half-life of FR901228, we selected the direct injection route rather than the intravenous injection route. We tested several concentrations of FR901228 in intravenous and intraperitoneal injection. Using intravenous injection, approximately , and pcDNA3 with FR901228 (pcDNA3/ GCV+FR; n ¼ 12) or pcDNA3 alone (pcDNA3/GCV; n ¼ 15). FR901228 (1 mg/body) was mixed with HVJ-liposomes and used. All these animals were i.p. injected with GCV once daily for 5 days. (b) Survival of mice was monitored after six-times injection of HSV-tk/GCV+FR901228 (HSV-tk/ GCV+FR, 6 injections, n ¼ 18) or HSV-tk/GCV alone (HSV-tk/GCV, 6 injections, n ¼ 16). The survival data were analyzed by log rank test. Consecutive treatment with HSV-tk/GCV+FR was more effective than consecutive injection of HSV-tk/GCV(P ¼ .021).
Enhanced gene therapy of melanoma S Yamamoto et al 5-10 times higher concentrations of FR901228 were needed to increase gene expression to the same level as the concentration in direct injection. In i.p. injection, more than 200 times concentration was needed. The longterm existence of lower concentration FR901228 in the target organ is most appropriate in terms of safety and efficacious therapy. Controlled release of FR901228 with a microcapsule may also result in more effective enhancement of therapeutic genes for cancer treatment.
Retention of a therapeutic gene by cancer cells is also necessary for an effective vector. One strategy to sustain gene expression is consecutive transfection. Gene transfer to the melanoma tumors has been achieved with HVJliposomes. Although a single injection of HSV-tk/GCV or FR901228 reduced tumor volume transiently (Fig 4) , tumors began to grow again after day 13. Thus, a single injection of HSV-tk/GCV or FR901228 was insufficient for mice survival (Fig 5a) . HVJ-liposomes containing HSV-tk gene can be injected consecutively because of their low immunogenicity. 37 Subsequently, we conducted the consecutive injection of HSV-tk gene-loaded HVJliposome combined with FR901228. In our present study, consecutive treatment with HSV-tk/GCV and FR901228 resulted in the significantly prolonged mouse survival compared with that obtained with HSV-tk/GCV alone (Fig 5b) . Epstein-Barr virus (EBV) replicon plasmid will provide more effective sustained gene expression as described previously. 38 The expression of luciferase gene cloned in EBV plasmid also increased with FR901228 (Yamano, unpublished data) .
In this experiment, we combined FR901228 with suicide gene therapy. Since FR901228 generally activates exogenous gene expression, combinations of FR901228 with other cancer gene therapy strategies may also be available for cancer treatment. Suicide gene therapy is known to have multiple anticancer effects. With suicide gene therapy, all cancer cells can be killed despite low transfection efficiency (bystander effect). 17 Furthermore, suicide gene therapy can induce tumor immunity. 18 In addition, it is reported that HDAC inhibitors mediate the expression of cell surface proteins such as CD86, 39 ICAMI, 39 and MAGE3. 40 These reports suggest the possibility of the use of HDAC inhibitors for increasing the expression of tumor-associated antigens. Moreover, in our experiment, mice cured from melanoma by suicide gene therapy showed strong delayed-type hypersensitivity (DTH) reaction after injection of recombinant tumorassociated antigens such as gp100 and TRP2 into the footpad (data not shown). Those mice also produced antibodies of very high titer (final liter: 6400-12 800) against gp100 and TRP2. Host immune responses against melanoma-associated antigens were significantly increased by the treatment of HSV-tk/GCV combined with FR901228.
Consequently, approximately two-thirds of those mice rejected melanoma when rechallenged with melanoma (Yamamoto, unpublished data). Therefore, it is expected that the combination of suicide gene therapy and FR901228 may efficiently prevent metastasis or regress metastatic foci of malignant melanoma.
